Mustbio leverage our innovative platforms, BICSTA™ and STARKINE™, to develop tumor-directed multi-specific antibodies with broader therapeutic potential. Mustbio is committed to creating next-generation immuno-oncology therapies, ensuring that patients receive safer and more effective treatment options. Through continuous research and development, and active collaboration with global partners, we aim to revolutionize cancer care and improve patient outcomes.

BICSTA™ allows efficient production of asymmetric multispecific antibodies similar to the natural form of IgG. The technology offers superior yield in generating multispecific antibodies, enabling diverse configuration applications. STARKINE™ facilitates generation of novel cytokine variants through rational design and computational modeling.

Private

Biotech